文献速递肝病消化道肿瘤与早癌

2021年肝细胞癌诊断与管理:一项全国退伍军人事务部质量改进项目

Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-07-15

本研究从电子健康记录中识别2021年新诊断肝细胞癌的退伍军人2306例,由专家审查者对10%随机子样本进行结构化病历提取。在199例确诊患者中,54%为早期(T1或T2),73%接受肝癌导向治疗,35%接受潜在治愈性治疗;早期诊断、退伍军人事务部系统内诊断和接受治愈性治疗与生存显著相关。

要点

  • 199例确诊肝细胞癌患者中54%诊断时为早期(T1或T2),73%接受肝癌导向治疗。
  • 从诊断到治疗的中位时间为37天(四分位距19-54天),35%接受潜在治愈性治疗。
  • 早期诊断、退伍军人事务部系统内诊断和接受治愈性治疗与生存显著相关。

核心结论

  • 结果强调肝细胞癌筛查和参与诊疗对诊断、治疗和生存的重要性,并展示制定全国性肝细胞癌筛查、诊断和治疗质量改进议程的可行性。

研究设计与样本

  • 质量改进项目,从电子健康记录中识别2021年新诊断肝细胞癌的退伍军人2306例。
  • 由专家审查者对10%随机子样本进行结构化病历提取。
  • 采用多变量模型评估与诊断分期、接受治疗和生存相关的因素。

主要发现

  • 在199例确诊肝细胞癌患者中,平均年龄71岁,72%有 underlying cirrhosis。
  • 超过一半(54%)诊断时为早期(T1或T2)。
  • 145例(73%)患者接受肝癌导向治疗,中位时间37天(四分位距19-54天),其中70例(35%)接受潜在治愈性治疗。
  • 较不晚期肝病、适合肝癌筛查的影像学检查数量、在退伍军人事务部系统内诊断和接受退伍军人事务部初级保健与早期诊断显著相关。
  • 肝癌筛查、诊断时早期和较好体能状态与接受潜在治愈性(vs无)治疗相关;较少合并症和较好体能状态与非治愈性(vs无)治疗显著相关。

关键数值与推荐

  • 早期阶段定义为T1或T2。
  • 潜在治愈性治疗70例(35%)。
  • 肝癌导向治疗145例(73%),中位37天(四分位距19-54天)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The coronavirus disease-2019 pandemic profoundly disrupted preventative health care services including cancer screening. As the largest provider of cirrhosis care in the United States, the Department of Veterans Affairs (VA) National Gastroenterology and Hepatology Program aimed to assess factors associated with hepatocellular carcinoma (HCC) stage at diagnosis, treatment, and survival. METHODS: Veterans with a new diagnosis of HCC in 2021 were identified from electronic health records (N = 2306). Structured medical record extraction was performed by expert reviewers in a 10% random subsample of Veterans with new HCC diagnoses. Factors associated with stage at diagnosis, receipt of treatment, and survival were assessed using multivariable models. RESULTS: Among 199 patients with confirmed HCC, the average age was 71 years and most (72%) had underlying cirrhosis. More than half (54%) were at an early stage (T1 or T2) at diagnosis. Less-advanced liver disease, number of imaging tests adequate for HCC screening, HCC diagnosis in the VA, and receipt of VA primary care were associated significantly with early stage diagnosis. HCC-directed treatments were administered to 145 (73%) patients after a median of 37 days (interquartile range, 19-54 d) from diagnosis, including 70 (35%) patients who received potentially curative treatments. Factors associated with potentially curative (vs no) treatments included HCC screening, early stage at diagnosis, and better performance status. Having fewer comorbidities and better performance status were associated significantly with noncurative (vs no) treatment. Early stage diagnosis, diagnosis in the VA system, and receipt of curative treatment were associated significantly with survival. CONCLUSIONS: These results highlight the importance of HCC screening and engagement in care for HCC diagnosis, treatment, and survival while demonstrating the feasibility of developing a national quality improvement agenda for HCC screening, diagnosis, and treatment.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rogal SS, Taddei TH, Monto A, et al. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project. Clin Gastroenterol Hepatol. 2023. PMID: 37460005. doi:10.1016/j.cgh.2023.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。